Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Oct 06, 2026
TickeronGET DAILY SIGNALS
Why Is Option Care Health (OPCH) Stock Up +32.91% Today?

Why Is Option Care Health (OPCH) Stock Up +32.91% Today?

Key Takeaways

  • OPCH shares jumped roughly 32.9% to about $31.06, from a prior close of $23.37.
  • The primary catalyst is a definitive agreement for private equity firm Clayton, Dubilier & Rice (CD&R) and McKesson to acquire Option Care Health for $32.05 per share, or roughly $5.8 billion in enterprise value.
  • The agreed price represents a premium of approximately 37% to the October 5 closing price.
  • CD&R will hold about 51% and McKesson about 49%, with a framework for McKesson to later acquire CD&R's stake.
  • Secondary support came from analyst commentary, including Truist reiterating a Buy rating.
  • Traders are now watching the gap between the current price and the $32.05 deal price, plus regulatory and shareholder approvals ahead of an expected first-half 2027 close.

Opening Summary

Option Care Health, Inc. (OPCH), the largest independent provider of home and alternate-site infusion services in the United States, staged a powerful rally on Tuesday. Shares climbed about 32.9% to trade near $31.06, up from a prior closing price of $23.37. The move followed the announcement that CD&R and McKesson (MCK) had signed a definitive agreement to acquire the company, taking it private at $32.05 per share.

The Definitive Acquisition Agreement

The decisive driver behind the surge was a confirmed buyout. Under the terms, CD&R and McKesson will acquire OPCH for $32.05 per share in cash, valuing the company at approximately $5.8 billion including debt. The agreed price reflects a premium of roughly 37% over the October 5 closing price, explaining the sharp repricing of the stock toward the deal value.

At closing, CD&R is expected to hold a majority interest of about 51%, while McKesson will invest roughly $1.4 billion for a minority stake of about 49%. The agreement also establishes a framework for McKesson to acquire CD&R's interest in the future, subject to specified conditions and regulatory approvals. Option Care Health is expected to remain a separate company led by its existing management team.

Strategic Rationale and Sector Context

The transaction underscores growing strategic interest in home and community-based infusion care, a segment benefiting from an aging population and the shift of care toward lower-cost, patient-preferred settings. McKesson framed the investment as aligned with its long-term strategy to expand access and affordability for specialty and complex therapies across the care continuum. The deal is also the latest in a series of private equity acquisitions targeting home health services providers, reinforcing investor appetite for the sector.

Analyst Reaction

Analyst commentary provided secondary support. Truist Securities reiterated a Buy rating, citing Option Care Health's strong payer relationships, including in-network status with the top ten plans and coverage of roughly 96% of insured lives, as well as the company's free-cash-flow generation. The firm pointed to the platform's strategic positioning amid durable demand drivers in infusion and alternate-site care.

Market Context and Trading Activity

Trading volume was heavily elevated relative to typical sessions as investors repriced OPCH toward the announced deal value. The rally was company-specific rather than a broad market event, with the stock's move far outpacing the major indices. Notably, the shares settled somewhat below the $32.05 offer price, reflecting a deal spread that accounts for the time to closing and the customary execution risks associated with a transaction expected to complete in the first half of 2027.

What Comes Next for OPCH

The path ahead for OPCH will be shaped primarily by the mechanics of completing the transaction. Shareholders must approve the deal, and the closing remains subject to required regulatory approvals and other customary conditions. Given the expected first-half 2027 completion timeline, the stock is likely to track developments around regulatory review and any potential changes to deal terms. A termination of the agreement would expose shares to downside toward pre-announcement levels. The company's previously reported second-quarter results beat consensus estimates, with adjusted EPS of $0.45 versus expectations of $0.43 and revenue of $1.44 billion, providing fundamental context amid the acquisition-driven repricing.

Trending AI Robots

For traders seeking a systematic approach to markets like this, Tickeron's Trending AI Robots page offers a curated view of AI-driven trading bots. Tickeron provides hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in this section. Bots vary by strategy, timeframe, performance metrics, and traded symbols, allowing users to explore automated approaches suited to their objectives. Visit the Trending AI Robots page to discover which strategies are currently leading.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: OPCH

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


OPCH sees MACD Histogram crosses below signal line

OPCH saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 26, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 48 instances where the indicator turned negative. In 37 of the 48 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 77%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 22 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 45 of 73 cases where OPCH's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 62%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where OPCH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 65%.

OPCH broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 06, 2026. You may want to consider a long position or call options on OPCH as a result. In 57 of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 59%.

OPCH moved above its 50-day moving average on October 06, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for OPCH crossed bullishly above the 50-day moving average on October 07, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 69%.

The 50-day moving average for OPCH moved above the 200-day moving average on October 29, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a +0.22% 3-day Advance, the price is estimated to grow further. Considering data from situations where OPCH advanced for three days, in 174 of 292 cases, the price rose further within the following month. The odds of a continued upward trend are 60%.

The Aroon Indicator entered an Uptrend today. In 158 of 221 cases where OPCH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 71%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 32 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. OPCH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 54 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 70 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OPCH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock better than average.

The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.763) is normal, around the industry mean (204.532). P/E Ratio (23.797) is within average values for comparable stocks, (21.572). Projected Growth (PEG Ratio) (1.101) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.154) among similar stocks. P/S Ratio (0.682) is also within normal values, averaging (2.688).

Notable companies

The most notable companies in this group are DaVita (NYSE:DVA), Community Health Systems (NYSE:CYH), WW International Inc (NASDAQ:WW).

Industry description

Hospital/Nursing Management companies own and operate health care facilities. Their operations include nursing homes, acute care facilities, retirement centers and outpatient surgery centers. HCA Healthcare Inc., Alcon Inc. and Universal Health Services, Inc. are some major companies in this industry. Technology has been at the forefront of development of advanced solutions, including quicker diagnoses of complex conditions. Investments in new diagnostics, healthcare IoT, and other healthcare technologies continue to gather momentum in this industry.

Market Cap

The average market capitalization across the Hospital/Nursing Management Industry is 5.37B. The market cap for tickers in the group ranges from 20.9K to 107.17B. HCA holds the highest valuation in this group at 107.17B. The lowest valued company is NMMCF at 20.9K.

High and low price notable news

The average weekly price growth across all stocks in the Hospital/Nursing Management Industry was -2%. For the same Industry, the average monthly price growth was 2%, and the average quarterly price growth was 12%. ARDT experienced the highest price growth at 44%, while AIRS experienced the biggest fall at -69%.

Volume

The average weekly volume growth across all stocks in the Hospital/Nursing Management Industry was 111%. For the same stocks of the Industry, the average monthly volume growth was 75% and the average quarterly volume growth was 8%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 45
Price Growth Rating: 51
SMR Rating: 66
Profit Risk Rating: 82
Seasonality Score: -1 (-100 ... +100)
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a provider of home and alternate site infusion services.

Industry HospitalNursingManagement

Industry
N/A
Address
3000 Lakeside Drive
Phone
+1 312 940-2443
Employees
8266
Web
https://www.optioncarehealth.com
Interact to see
Advertisement
The Bitwise Solana Staking ETF (BSOL) advanced roughly 18% over the trailing 30 days, closely tracking a sharp rally in Solana (SOL). The move extends a broader recovery, with BSOL up approximately 77% over the past three months from its mid-2026 trough.
MSTY is an actively managed single-stock option income ETF (exchange-traded fund) that writes call options on Strategy (MSTR), formerly MicroStrategy, to generate current income. The portfolio is anchored by U.S. Treasury bills and MSTR option contracts rather than a diversified basket of equities, concentrating exposure in one volatile underlying.
AMDL has surged roughly +64% over the past 30 days, from about $47.59 to $78.10, mirroring a powerful rally in its sole underlying stock, AMD . The fund is a leveraged single-stock ETF (exchange-traded fund) designed to deliver 2x the daily return of AMD, amplifying both gains and losses.
Palantir reported Q1 2026 revenue of $1.63 billion, up 85% year-over-year, beating consensus estimates of $1.54 billion. Adjusted EPS came in at $0.33, surpassing expectations of $0.28, with GAAP EPS at $0.34.
Analysts expect Q1 2026 revenues of approximately $13.8 billion, up slightly from $13.7 billion in Q1 2025. Consensus adjusted EPS estimate is around $0.72-$0.74 per share, down about 20% year-over-year from $0.92 due to product mix shifts and cost pressures.
Why Is Option Care Health (OPCH) Stock Up +32.91% Today?